Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05182957 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: 2 to 1v3 Show 5 more changesShow less
    • Enrollment target: 40 to 31
    • Primary completion date changed from estimate of Dec 14, 2023 to Dec 15, 2023
    • Study completion date: Dec 14, 2023 to Jun 15, 2026
    • Start date: Dec 14, 2022 to Jan 1, 2020
    • Secondary endpoints revised (4)
  2. Primary and study completion dates: Dec 14, 2022 to Dec 14, 2023
    • Start date: Dec 14, 2021 to Dec 14, 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
Trial Details
NCT Number NCT05182957
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Relapsed/Refractory Peripheral T-cell Lymphoma
Related terms Lymphoma, T-Cell, Peripheral
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov